Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: robert packman who wrote (767)	3/14/1998 12:08:00 PM
From: Amigo Mike	Read Replies (1) \| Respond to of 1476

We seem to get stuck each time we reach $1.25 lately. Hmmmmmm. Mike

To: robert packman who wrote (767)	3/19/1998 12:30:00 PM
From: John R Resseger	Respond to of 1476

PATENTS AND OTHER RIGHTS The Company has forty-four allowed or issued U.S. and international patents. Currently there are ten pending patent applications in the United States, with corresponding international patent applications. Two of the issued patents and one of the U.S. patent applications, and the corresponding foreign patent applications, are co-owned with other entities. The majority of the patent applications relate to the Company's ART and NST. Collectively, the applications include composition claims for enhanced bacteria, receptors and their corresponding adhesins or toxins, method of use claims for the use of these compositions, for vaccines and for other antimicrobial products. The Company holds licenses for exclusive rights to patents and related technologies covering VeroTest(R) and certain H. pylori products. The Company has made initial payments to the licensors and is obligated to timely pay certain royalties or these licenses may be converted to non-exclusive licenses. In addition, royalty payments must be made if the Company markets products or services incorporating the licensed technologies.